A technology-driven sleep therapy solution has taken a major step towards capturing a share of the global $80bn/£57bn sleep aid market after securing US regulatory registration.
SleepCogni, a data-supported device which uses haptic feedback to break cognitive cycles, has now been registered for medical use by the US Food & Drug Administration (FDA).
Co-founded by Sheffield-based entrepreneur Richard Mills, who has personally suffered from sleeping disorders, and Dutch chronobiologist and sleep expert, Dr Maan van de Werken, SleepCogni is a hand-held sleeping aid which enables users to self-manage their insomnia.
It provides users with an immediate sleep aid whilst simultaneously collecting data from 15 sensors to provide informed insight for clinical intervention, including Cognitive Behavioural Therapy for insomnia.
The device has secured 11 patents including ones for its wind down technology and Active-Biofeedback.
Following a successful clinical trial at Sheffield Hallam University, preliminary analysis has shown that SleepCogni reduces insomnia – as measured by Insomnia Severity Index – in seven days.
FDA registration opens up immediate access to an estimated 70m sleep sufferers living in the US.
Since it was founded in 2015, SleepCogni has raised almost £1.8m to support technology development, including investment from venture capitalists Mercia and other private sources, and has secured three research and development grants through the UK’s innovation agency, Innovate UK.
The company is now about to begin beta testing its device at four sites, two in the UK and two in the US, one of which is a world-leading healthcare system.
Upon successful testing, SleepCogni is set to be rolled out to 130 clinics of one of the largest sleep care management groups in the US.
site:https://www.thebusinessdesk.com/yorkshire/news/2076442-tech-enabled-insomnia-therapy-poised-to-break-into-global-sleep-aid-market
No comments:
Post a Comment